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Abstract
Neonates represent a unique and highly vulnerable patient population. Advances in 
medical technology have improved the survival and quality of life of newborns, particu-
larly those with extreme prematurity or with congenital defects. Furthermore, immu-
nologic immaturity and altered cutaneous barriers play some role in the vulnerability 
of neonates to nosocomial infections. In this context, the incidence of invasive fungal 
infections has increased significantly worldwide, representing an important infective 
complication in patients hospitalized in intensive care units. Invasive fungal infections in 
Neonatal Intensive Care Unit (NICUs) show high mortality; being species of Candida, the 
most isolates etiologic agents. The better prognosis of the patient is associated with the 
early diagnosis and fast treatment. However, guidelines to facilitate the optimal therapy 
choice for the treatment of neonatal fungal disease do not exist. The current antifungal 
agents that are available to treat fungemia among newborns and children are based on 
clinical trials in adults, since there are few comparative studies of antifungal agents in 
infants. The most commonly used drugs for the treatment of invasive fungal infections in 
neonates are classified in four different classes: polyene, azoles, analogs of pyrimidines 
and echinocandins.
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1. Introduction
During the last two decades, invasive fungal infections in preterm infants have become an 
increasing problem, mainly when hospitalized in a Neonatal Intensive Care Unit (NICU). 
Thus, for the last years, 6.3 million children under the age of 5 died each year are estimated, 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
and more than 40% of these deaths occur in the neonatal period [1, 2]. These data have several 
causes and particularly the neonates are at high risk due to fungal infections, mainly by yeasts 
of the genus Candida [3, 4].
In addition, species of the genus Candida have the capacity to inhabit several niches, thus, as 
part of the skin, mucosa and gastrointestinal tract [5]. Therefore, is considered that there is an 
association between colonization and systemic candidiasis mainly in seriously ill patients [6].
Although Candida albicans are more frequent, species of Candida non-albicans are also cause of 
diverse clinical pictures important in neonates, especially those that are in NICUs. The main 
Candida non-albicans species included are Candida parapsilosis complex, Candida glabrata and 
Candida krusei. However, uncommon species as Pichia fabianii and Kodamaea ohmeri may occur 
[7–10].
The newborns clinical course in the Intensive Care Units usually complicates after the onset 
of fungal infections [11]. In this hospital environment, adverse events may occur due to the 
complexity of the patients [12]. In this sense, the treatments and procedures instituted for 
primary disease may be an important factor for the onset of fungal infections; birth weight 
between 1000 and 1500 g is also a predictive factor and a way for the clinical worsening [13].
The predisposing factors to fungal infections include prolonged use of antibacterial and use of 
medical devices, among other conditions that lead to fungal disease. In addition, biofilms are 
frequent on the surface of medical devices, being consider a negative event, since it character-
izes greater pathogenicity and antifungal resistance of fungi.
Commonly, amphotericin B, azoles and echinocandins are used for the treatment of various 
invasive fungal infections. However, antifungal therapeutic failures contribute to a higher 
mortality rate and may occur due to intrinsic resistance, so it is important to perform anti-
fungal sensitivity tests. These tests can predict the ideal antifungal or contribute in the choice 
according to the use of other medicines and the condition of the neonate [9].
2. Epidemiology and incidence of neonatal invasive fungal infections
Neonates represent a unique and highly vulnerable patient population. Advances in medical 
technology have improved the survival and quality of life of newborns, particularly those 
with extreme prematurity or with congenital defects. Immunologic immaturity and altered 
cutaneous barriers play some role in increasing the vulnerability of neonates to infections. 
In this context, neonatal infection is a major cause of mortality and morbidity in newborns. 
Estimates suggest that >1.4 million neonatal deaths worldwide annually are due to invasive 
infections [14, 15].
The occurrence of invasive fungal infections has increased significantly worldwide, repre-
senting an important infective complication in patients hospitalized in intensive care units. 
Premature infants in NICUs are at particular risk of these invasive fungal infections, and 
unfortunately, the incidence of fungal septicemia appears to be increasing [16, 17]. In this 
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context, Candida and Malassezia species are the most prevalent pathogen involved in fungal 
infections in NICU [18].
The incidence of bloodstream infections due to Candida species in the overall population 
ranges from 1.7 to 10 episodes per 100,000 inhabitants. An estimated 33–55% of all episodes 
of candidemia occur in intensive care units and are associated with mortality rates ranging 
from 5 to 71% [16].
Invasive candidiasis is an important cause of sepsis in the NICU. Candida infections in infants 
are associated with significant mortality and morbidity, including neurodevelopmental 
impairment. The incidence of invasive candidiasis in NICU ranges from 2.6 to 13.2% in very 
low birth weight infants (1500–1000 g) and from 6.6 to 26.0% in extremely low birth weight 
infants (<1000 g) [19].
C. albicans has been the most frequently isolated species; however, infections caused by others 
species have been diagnosed with increased frequency. In the NICU in the 1990s, the overall 
incidence of candidemia increased because of the increased survival and intensive care of 
extremely preterm infants. During that time period, the proportion of candidemia decreased 
because of C. albicans, whereas increased because of C. parapsilosis [20, 21].
Invasive infections associated with C. parapsilosis cause fewer acute lethal events in prema-
ture newborns than systemic infections with C. albicans; nevertheless, C. parapsilosis fungemia 
significantly increases the morbidity and mortality of severely ill infants who require care in 
a NICU [22].
Laboratory studies have documented that C. parapsilosis is less virulent than C. albicans. 
However, the capability to adhere tenaciously to prosthetic materials forming biofilm and 
to proliferate rapidly in high concentrations of glucose are factors that facilitate the infection 
in the hospital environment. This trait may contribute to its ability to adhere to plastic cath-
eters and cause systemic infections in premature newborns receiving total parenteral nutri-
tion, blood pressure transducers or other invasive devices. Such a route of transmission may 
account for the occurrence of epidemic outbreaks of C. parapsilosis bloodstream infections [21].
Other emerging Candida species such as C. haemuloniii, C. pelliculosa and C. tropicalis have also 
been associated with infections in NICU. C. pelliculosa and C. haemuloniii caused clonal infec-
tion in NICU [11]. An outbreak of C. tropicalis fungemia in a NICU was traced to receipt of 
total parenteral nutrition and antimicrobial agents [23].
Malassezia species in immunocompromised patients may be associated with several skin con-
ditions and systemic diseases, including folliculitis, seborrhoeic dermatitis, catheter-related 
fungemia and sepsis. However, this yeast may also cause invasive infections in critically ill 
low birth weight infants. Malassezia fungemia is predominantly caused by Malassezia furfur 
and Malassezia pachydermatis. M. furfur has been described predominantly in conjunction with 
nosocomial outbreaks in NICU, particularly in neonates and infants receiving intravenous 
lipids solution. Additionally, M. pachydermatis has been associated with bloodstream infec-
tion in preterm with very low birth weight and the prolonged use of indwelling catheters and 
parenteral lipid formulations [18, 24].
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3. Neonatal Candida infections
Candida species are correlated to invasive fungal infections among at-risk groups as neonatal 
patients admitted NICU in and have been ranked third to seventh as a cause of nosocomial 
bloodstream infection, defined as candidemia, depending on geographical patterns [25–28]. 
Studies on invasive candidiasis infections and candidemia are frequently focused on specific 
diagnoses and/or specific populations. In all published studies, ICU was the most frequent 
localization of the patients, even with different frequencies [29].
Candidemia is associated with high rates of illness and death and has an attributable mortal-
ity rate that varies widely in the literature, ranging from 29 to 76%, both in adult and pediatric 
patients [30, 31]. Furthermore, Candida species are common gastrointestinal flora that causes 
a wide range of severe manifestations when disseminated into the bloodstream. Thus, can-
didemia has been described as the most common manifestation of invasive candidiasis [32].
These yeasts are less frequent than those infections caused by Gram-positive or Gram-negative 
bacteria; nonetheless, they are higher rates of morbidity and mortality. Particularly, among 
newborn with extremely low weight, 10% may to develop candidemia that has until 30% mor-
tality in this patient group. Among infants who survive these infections, several long-term 
neurological impairments such as cerebral palsy, blindness, hearing and cognitive deficits 
and periventricular leukomalacia may occur [9, 27].
Neonatal candidemia during the first week of life is less common and less well described 
than the later onset of this group of infections. According to Barton et al. [33], risk factors for 
candidemia among neonates had not been studied before their research, in early onset disease 
(EOD, ≤7 days) or compared to late onset disease (LOD, >7 days). After a 2-year study, the 
authors concluded that risk factors such as birthweight <750 g, gestation <25 weeks, chorio-
amnionitis and vaginal delivery were strongly associated with EOD. Infection with Candida 
albicans, disseminated disease, pneumonia and cardiovascular disease were significantly 
more common in EOD than in LOD. Also, neurodevelopmental impairment and mortality 
were also higher than controls.
Extremely low birth weight is considered a risk factor related to a poor prognosis in EOD. 
Also, the role of perinatal transmission is supported by its association with chorioamnionitis, 
vaginal delivery and pneumonia. Dissemination and cardiovascular involvement are com-
mon, and affected infants often die. Empiric treatment should be considered in these risk 
situations [33, 34].
Pereira et al. [34] developed a retrospective observational study to investigate the risks for 
sepsis in neonates, including Candida infections, and verified an association between health-
care-associated sepsis, antibiotic therapy in day 1, the duration of parenteral nutrition and the 
use of central vascular catheter. For each extra week on gestational age, the risks declined in 
20%, and for each day of parenteral nutrition, the risk increased 22%.
Kung et al. [35] affirm that infants in NICU have a higher incidence of Candida infections than 
any other pediatric or adult population. The predisposing factors were evaluated in Taiwan 
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using a retrospective matched case-control study conducted in the NICUs of a teaching hos-
pital from July 2003 to June 2006. A total of 164 infants with culture-proven bloodstream 
infections were identified and the common etiologic pathogens included coagulase-negative 
staphylococci (28.7%), Staphylococcus aureus (16.5%), Klebsiella pneumoniae (14.6%) and Candida 
species accounting for 11 (6.7%) episodes. According to these authors, parenteral nutrition 
was a significant and independent risk of late-onset neonatal sepsis, including those caused 
by Candida species. This risk should be considered when implementing early parenteral nutri-
tion in NICUs.
The collected potential risk factors consisted of: (1) prenatal and maternal history such as 
toxemia, multiple gestation, intra-uterine growth retardation and perinatal infections; 
(2) perinatal history such as premature rupture of membrane greater than 18 hours and delay 
in initial crying; (3) invasive procedures such as instrument insertion and its duration (e.g., 
placement of nasogastric tubes, endotracheal tubes, mechanical ventilation, peripherally 
inserted central catheters, chest tubes, blood transfusion or exchanged blood transfusion and 
lumbar puncture); (4) the concomitant use of medications such as parenteral nutrition and 
intravenous lipid, antibiotics and steroids and (5) comorbidities such as meconium aspiration 
syndrome (MAS), persistent pulmonary hypertension of the newborn (PPHN), intraventricu-
lar hemorrhage (IVH), necrotizing enterocolitis (NEC), respiratory distress syndrome (RDS), 
inborn error of metabolism and cardiac anomalies (except for patent ductus arteriosus and 
secundum type of atrial septal defect). However, transfusion, antimicrobial treatment, use of 
steroids and the presence of other comorbidities were not associated with Candida infections 
in neonates [35].
Invasive neonatal candidiasis presented an overall mortality rate of 35% during a study in Los 
Angeles (USA) in a neonatal intensive care unit. In general, every infant used a central venous 
catheter (CVC), required mechanical ventilation and previous administration of antibacterial 
agents. According to the authors, delayed institution of antifungal therapy was associated 
with increased mortality as well as length of hospitalization and the duration of prior anti-
bacterial therapy [36].
Frequently, C. albicans is the most fungal clinical isolate; however, the incidence of bloodstream 
infections caused by Candida non-albicans, mainly C. parapsilosis complex and C. glabrata, has 
increased over the past 15 years. The current high rate of Candida parapsilosis infections may 
be attributed the capacity of this isolate to form biofilms and contaminate solutions, as those 
used in parenteral nutrition [8].
In recent Italian study, C. albicans was the most frequently identified strain, but nearly 20% of 
infections were due to Candida non-albicans, mainly C. krusei and C. glabrata [10]. Since both 
these strains can be resistant to fluconazole, that is the antifungal drug with the best urinary 
penetration [37], treatment of these patients could be challenging, despite a recent report that 
showed effective concentrations of micafungin in the urinary tract [38]. In these search, funge-
mia was the second most frequent diagnosis and was more frequent in children with malig-
nancy/hematopoietic stem cell transplantation, those undergoing abdominal surgery and in low 
birth weight neonates, also in this case, confirming other recent pediatric data such as Ota et al. 
[39] and Steinbach et al. [40].
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Invasive fungal infections in NICUs show high mortality. The better prognosis of the patient 
with invasive candidiasis/or candidemia admitted in NICU is associated with the early diag-
nosis and fast treatment. Evidence suggests an estimated mortality rate of 40% if therapy is 
not initiated early. Therefore, it is not a good practice to wait for cultures to become positive. 
This need for early therapy must be balanced against the need to use antifungal agents to 
avoid selection of resistant strains. Early empiric therapy guided by stratification systems for 
high-risk patients should help address these cases [41].
The score for exact risk measurement of invasive candidiasis has yet to be developed. The 
“Candida Score” presented by Spanish group in 2006 provides an easy-to-use tool to assist 
the health professionals with critically ill adults [42]. However, we believe that will should be 
adapted to pediatric patients, in the near future. In this stratification, the selected variables 
by logistic regression model with increasing weight are total parenteral nutrition, surgery, 
multifocal Candida species colonization and severe sepsis [42].
Recent Infectious Disease Society American guidelines suggest that “empirical antifungal 
therapy should be considered in critically ill patients with risk factors for invasive candidiasis 
and no other known cause of fever.” Risk factors for invasive candidiasis are well identi-
fied. When analyzing clinical data, surveillance culture and levels of anti-Candida antibodies 
plus β-D-glucan in the serum, the same Spanish researchers showed a positive correlation 
among increasing values of the “Candida score” and the rate of invasive Candida infections. 
Such a score was calculated by variables such as total parenteral nutrition, surgery, multifocal 
Candida colonization and severe sepsis. Thus, Candida score ≥3 suggest patients at high risk 
for invasive candidiasis and enable to differentiate patients who would benefit from early 
antifungal treatment from those for whom invasive candidiasis is highly improbable [43].
4. Other neonatal fungal infections
Despite C. albicans is known to be primarily responsible for most neonatal fungal diseases, the 
prevalence of infections caused by other fungi in neonates and young infants is not signifi-
cant, except for Malassezia species, which may occur in epidemic outbreaks [44–46].
Since 1980, this genus has been recognized in sepsis and systemic infections involving neo-
nates receiving lipidic parenteral nutrition using a central venous catheter. It is believed that 
lipid supplementation facilitates the colonization of the catheter that used to infuse the nutri-
ents. In newborns, colonization by Malassezia can progress to fungemia. The removal of the 
infected catheter is sufficient to limit infection in most cases [46, 47].
The vast majority of cases of fungemia occur in children less than 12 months old. In this 
population, this Malassezia infection rarely remains asymptomatic. Interstitial pneumonia and 
thrombocytopenia are common clinical manifestations in this group of patients, and the most 
frequent symptoms in systemic infections are fever and respiratory dysfunction with or with-
out apnea [46, 48].
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Other less common symptoms include lethargy, malnutrition, bradycardia and hepatospleno-
megaly. However, no signs of erythema, swelling or purulence appear at the catheter entry 
site. Signs of skin rash are also not evident in children with systemic infections. Interstitial 
bronchopneumonia can be found in 40% of children [44–46].
The diagnosis of fungal infection by Malassezia is made by isolating the microorganism from 
blood collected through the catheter or by culturing the catheter tip after its removal. In sus-
pected sepsis by Malassezia, the tip of the catheter should be cultured in broth enriched with 
lipids [45, 46].
The standard therapeutic management for systemic infections by Malassezia is still not well 
defined, since the fungemia by this microorganism is relatively unusual. However, some 
authors recommend the use of amphotericin B to treat these infections [45, 46, 49]. Morrison 
and Weisdorf [50] found that all patients enrolled in their study were cured without the 
administration of systemic antifungal therapy.
Studies have indicated that the most important factor for therapeutic success against systemic 
infection is the removal of the infected catheter and the interruption of lipid infusion, with or 
without antifungals [18, 45, 46].
5. Treatment of neonatal fungal infections
The appropriate use of antifungals agents is of particular importance in the prevention and 
treatment of invasive fungal infection in neonates; however, guidelines to facilitate the opti-
mal therapy choice do not exist. The current therapeutic options that are available to treat 
fungemia among newborns and children are based on clinical trials in adults, since there 
are few comparative studies of antifungal agents in infants. The optimal treatment of fungal 
infection in this special population requires detailed studies on pharmacokinetics, safety and 
efficacy of antifungal therapies [51–54].
Similar to neonatal invasive infections by species of Candida, the management of Malassezia 
sp. fungemia requires the removal of any catheter as soon as the first positive blood cul-
ture occurs and the temporary discontinuation of parenteral nutrition in combination with 
an intravenous antifungal therapy. The most commonly used agents for the treatment of 
invasive fungal infections in NICU are classified into four different classes: polyene, azoles, 
analogs of pyrimidines and echinocandins. Among many years, the drugs of choice in this 
group of patients were amphotericin B alone or in combination with fluocitosin, liposomal 
formulation of amphotericin B or fluconazole. However, the development of a new genera-
tion of azoles and echinocandins, such as micafungin, has increased the therapeutic options 
for the treatment [45, 54].
Amphotericin B deoxycholate and lipid preparations are traditional choices for invasive 
fungal infections being active against a majority of clinical important Candida species and 
with reported use for Malassezia [45, 55]. Amphotericin B deoxycholate is well tolerated 
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by neonates who do not exhibit many of the toxicities seen in older children and adults. 
However, liposomal amphotericin B has been found to be safe and efficacious in newborns 
with renal impairment. Another polyene agent, nystatin suspension, is administered orally 
to infants with gestational age ≤ 27 weeks or birth weight less than 750 g until removal of 
central venous catheters; this is shown to reduce colonization of the gastrointestinal tract 
and the rate of invasive candidiasis [55].
Among the azoles, fluconazole is more frequently used in NICUs for the treatment of oropha-
ryngeal and systemic candidiasis, but has no inherent activity against the genus Aspergillus, 
which is rare pathogen in neonates. This antifungal agent is commonly recommended as pro-
phylactic therapy in NICU with a high incidence in fungal infections. Fluconazole prophy-
laxis is effective in reducing the rate of colonization and progression to systemic infection in 
nursery; on the other hand, some studies have revealed that prophylactic or empiric therapy 
with antifungal agents may be associated with changes in Candida ecology and antifungal 
agent susceptibility. Actually, the fluconazole dose recommended for neonates is 6 mg/kg/
day, and maintenance doses currently used in NICUs in Europe is often higher, between 6 
and 12 mg/kg [53, 56–58].
New azoles such as voriconazole, posaconazole and ravuconazole have limited utility in the 
nursery and are rarely used to treat neonatal infections. Voriconazole is a second-genera-
tion triazole that has excellent activity against Candida and Aspergillus spp.; however, data 
on its use in neonates are limited. Posaconazole and ravuconazole are the newest agents of 
the triazole family with added action against zygomycetes, however there are scarces of sur-
vey involving these antifungal agents in infants and the use of ravuconazole is not already 
approved by the Food and Drug Administration (FDA) [59, 60].
The echinocandins (micafungin, caspofungin and anidulafungin) are increasingly used for 
treatment of Candida sp. infections. Their role in the nursery is not so clear, although accru-
ing evidence suggests they may be safe and effective, especially for the treatment of invasive 
infections caused by Candida spp. Some point have to be taken under consideration before the 
use of echinocandins in NICUs: first, limited clinical data also suggest that these agents may 
be effective for the treatment of central nervous system infections. Second, a high incidence 
of C. parapsilosis in NICUs is usually reported and this species is related to higher minimum 
inhibitory concentration (MIC) front of echinocandins [56, 57].
Among the three representatives of the group, micafungin is the most recommended and 
its use is approved for adults, children and newborns, being considered the one with better 
description for neonatal population. The use of caspofungin is approved by the FDA, but only 
for adults and children over 3 months of age. There were no relevant clinical trials that sup-
port the administration of anidulafungin among neonates and children [56, 57].
Invasive fungal infections are devastating pathologies that still result in death or serious long-
term morbidity in neonates; however, the management of this mycosis has progressed greatly, 
with the azole agents playing a significant role. Effective prophylactic strategies have recently 
become available; therefore, the choice and use of appropriate antifungal drugs need careful 
assessment of neonatal characteristics, the epidemiology and drug pharmacokinetics [53].
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